คลังวิทยาศาสตร์

GlyNAC

Glycine + N-acetylcysteine

ระดับหลักฐานระดับหลักฐาน C

ดูบันทึกหลักฐานอิสระที่อธิบายด้วยภาษาที่เข้าใจง่าย ระดับหลักฐานแต่ละระดับตอบคำถามวิจัยที่กำหนดและไม่ใช่คะแนนของผลิตภัณฑ์

ทบทวนล่าสุด: 22 Aug 2026

IN PLAIN LANGUAGE

Why people are interested

Combines glycine and N-acetylcysteine, two substrates used in glutathione synthesis; mechanism does not establish a clinical outcome.

Outcome map

One ingredient. Different questions.

Each row answers a separate question; evidence strength can differ by outcome.

01
Glutathione synthesis mechanism
Glycine and cysteine are used in glutathione synthesis, but established biochemistry does not guarantee a clinical benefit.
Level A
02
Selected low-GSH older adults
One very small 16-week trial increased muscle and red-cell glutathione in a selected group, without independent replication.
Level B
03
Whole-blood glutathione
A larger 14-day trial in generally healthy older adults was null on its prespecified whole-blood glutathione endpoint.
Level C
04
Physical function
Preliminary signals come from one small trial not powered for function and an uncontrolled pilot, without replicated disability outcomes.
Level C
05
Cognition
Cognitive evidence rests on an eight-person uncontrolled pilot and does not establish a reliable benefit or prevention effect.
Level D
06
Healthy aging and lifespan
No human trial establishes disease prevention, slower biological aging, longer healthspan or longer life from GlyNAC.
Level E

How it may work

Combines glycine and N-acetylcysteine, two substrates used in glutathione synthesis; mechanism does not establish a clinical outcome.

What people have studied

GlyNAC has early, mixed human evidence. One very small 16-week randomized trial in selected older adults increased muscle and red-cell glutathione and generated preliminary physical-function signals, but a larger 14-day trial in generally healthy older adults was null on its prespecified whole-blood glutathione endpoint. Cognition rests on an eight-person uncontrolled pilot, and no human trial establishes disease prevention, slower aging or longer life.

What to consider

Short, selected studies cannot establish universal or long-term safety. Evidence for glycine or NAC alone does not automatically transfer to their combination, and NAC has medicine, route and medical-context considerations.

Local pathway

The exact ingredient combination, strength, format and claims require specialist local classification before commercialization.

แหล่งข้อมูล